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During the past two decades the use and reﬁnements of imaging modalities have markedly increased
making it possible to image embryos and fetuses used in pivotal nonclinical studies submitted to reg-
ulatory agencies. Implementing these technologies into the Good Laboratory Practice environment re-
quires rigorous testing, validation, and documentation to ensure the reproducibility of data. A workshop
on current practices and regulatory requirements was held with the goal of deﬁning minimal criteria for
the proper implementation of these technologies and subsequent submission to regulatory agencies.
Micro-computed tomography (micro-CT) is especially well suited for high-throughput evaluations, and is
gaining popularity to evaluate fetal skeletons to assess the potential developmental toxicity of test
agents. This workshop was convened to help scientists in the developmental toxicology ﬁeld understandimensional; CRO, contract research organization; DART, developmental and reproductive toxicology; EFD, embryo-fetal
FDA, Food and Drug Administration; GD, gestation day; GLP, Good Laboratory Practice; HESI, Health and Environmental
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; KOH, potassium hy-
micro-CT, micro-computed tomography; MRI, magnetic resonance imaging; NOAEL, no-observed-adverse-effect level;
evelopment; QAU, quality assurance unit; SOP, standard operating procedure; US, United States.
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GLP validationand apply micro-CT technology to nonclinical toxicology studies and facilitate the regulatory acceptance
of imaging data. Presentations and workshop discussions covered: (1) principles of micro-CT fetal im-
aging; (2) concordance of ﬁndings with conventional skeletal evaluations; and (3) regulatory re-
quirements for validating the system. Establishing these requirements for micro-CT examination can
provide a path forward for laboratories considering implementing this technology and provide regula-
tory agencies with a basis to consider the acceptability of data generated via this technology.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
On April 20e21, 2015, a workshop sponsored by the Health and
Environmental Science Institute's (HESI) Developmental and
Reproductive Toxicology (DART) Technical Committee entitled
“Fetal Imaging in Regulatory Developmental Toxicity Studies” was
held in Arlington, Virginia. The workshop brought together in-
dividuals from industry [chemical, pharmaceutical and contract
research organizations (CROs)], regulatory agencies, and academia
to discuss the state of the art of imaging technologies and how
these methods might be applied to regulatory studies, with a
speciﬁc focus on embryo-fetal development (EFD) studies, also
known as prenatal developmental toxicity studies, that evaluate
fetal skeletons from laboratory animals for morphological abnor-
malities. This manuscript provides a report on the proceedings and
summarizes the recommended acceptance criteria and next steps
identiﬁed by the scientists who participated in the workshop for
adherence to scientiﬁc principles as well as to requirements from
regulatory agencies.1.1. Background on methodology
1.1.1. Current regulatory guideline studies for fetal evaluation
National and international guidelines for the registration of new
pharmaceuticals and environmental chemicals, including pesti-
cides, typically require assessment of the potential to induce
developmental toxicity in laboratory animals. Some of these studies
currently involve administering the test agent to pregnant labora-
tory animals at various dose levels during gestation, either during
the period of organogenesis (ICH, 2005) or throughout the entire
period of in utero development (EPA, 1998; OECD, 2001), and sub-
sequently evaluating near-term fetuses for morphological abnor-
malities. These studies are typically termed EFD or prenatal
developmental toxicity studies. They are routinely conducted with
rodents and rabbits under Good Laboratory Practice (GLP) re-
quirements (EPA, 1989a,b; FDA, 1978) and are critical to hazard/risk
evaluation and the safety assessment process. The design and
reporting of EFD studies for pharmaceuticals has been described
(Wise et al., 2009) and study designs for environmental chemicals
are very similar, especially regarding fetal evaluations (EPA, 1998;
OECD, 2001). Evaluations for fetal external and visceral abnormal-
ities are required for all these studies, and an equally important
component of the evaluations is the assessment of the skeleton for
morphological abnormalities. Traditional skeletal evaluations have
been consistently conducted during the past 50 þ years where
laboratories conducting and submitting these studies for product
registration or hazard/risk evaluation have developed detailed
Standard Operating Procedures (SOPs) for the methods and
extensive historical control databases of fetal skeletal ﬁndings. The
standard procedure is to stain bone structures using alizarin red S
dissolved in dilute potassium hydroxide (KOH) (see Redfern and
Wise, 2007 and references therein). An additional stain for carti-
lage, alcian blue, is also sometimes used (see Redfern et al., 2007
and references therein). The staining process may be either auto-
mated, semi-automated, or manual. Specimens are examinedindividually, typically under magniﬁcation, by trained technicians,
and abnormalities are recorded manually or electronically using
standardized terminology (Makris et al., 2009). However, the
traditional methodology is laborious and resource intensive and
requires staining up to ~1200 rat or ~500 rabbit fetal specimens per
study and require relatively large quantities of hazardous sub-
stances (e.g., ethanol, KOH), and dedicated facilities for the staining
process and eventual archival of specimens.
1.1.2. Alternative methodologies
Over the past two decades there have been tremendous ad-
vancements in the design and use of various imaging modalities.
The purpose of this workshop was the use of micro-CT as an
alternative method for evaluating skeletal birth defects in animal
models and the capabilities of micro-CT as a high-throughput
method for skeletal evaluations (Winkelmann and Wise, 2009).
The implementation of such technology in a GLP environment,
however, requires extensive additional resources, including time,
effort, and costs. At this time, the technical methods, the results,
and their interpretation have not yet gained broad regulatory
acceptance thus a need for a collaborative workshopwas identiﬁed.
1.2. Workshop goals and organization
The primary aim of the workshopwas to develop considerations
and guidance for laboratories that are using or planning to use
micro-CT for skeletal evaluation in regulatory EFD studies and to
facilitate the regulatory acceptance of imaging data. The workshop
was organized to ﬁrst introduce and discuss image acquisition
technology, speciﬁcally micro-CT, relative to existing fetal evalua-
tion methodology. A segment was then devoted to discussing
various criteria to demonstrate concordance betweenmicro-CT and
existing fetal examination methods and testing results. Subsequent
presentations were intended to develop an understanding of the
regulatory community's perspective and the pathway for their
acceptance of data generated from imaging technology. This latter
topic included discussion of minimally acceptable criteria for im-
aging technologies, procedures, and data to comply with GLP and
computer validation requirements. Breakout discussions followed
each of these sessions; the areas of consensus across breakout
groups formed the basis for the recommended criteria and con-
siderations set forth in this paper. The ﬁnal session of the workshop
presented additional applications of micro-CT, including postnatal
assessment of skeletal abnormalities in rats, automated pheno-
typing of cardiovascular and other visceral abnormalities in mutant
mouse fetuses, and automated skeletal analysis of rabbit and rat
fetuses. Speciﬁc speaker topics can be found in Table 1.
The workshop focused on micro-CT-based skeletal evaluation
since this process is currently closest to implementation based on
recent publications (Winkelmann and Wise, 2009; Wise et al.,
2013). Any process that is implemented as an alternative to
replace conventional fetal evaluations should provide increased
speed and efﬁciency, while using reasonable resources. Micro-CT
has been shown to be well suited for high-throughput skeletal
evaluations, as well as offering a number of resource savings
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2009). Other imaging modalities were not discussed in detail dur-
ing the workshop, except to provide a high level comparison of
micro-CT to magnetic resonance imaging (MRI) and the use of MRI
and other modalities in academic laboratories to assess fetal mouse
phenotypes. The recommended criteria that were formulated
during this workshop, however, are envisioned to be similar for
adoption when a laboratory is ready to implement those other
modalities and/or processes.
2. Technical considerations: using micro-CT for fetal skeletal
evaluation
The primary aim of this sessionwas to inform the participants of
the current capabilities and limitations of micro-CT. With this
background, the participants would be prepared to consider the
criteria to be addressed by any laboratory considering imple-
menting this technology in routine nonclinical studies.
2.1. Background on technical considerations
Speakers provided an overview of the process involved in
acquiring, reconstructing, and analyzing three-dimensional (3-D)
images, each of which have separate systems, and some technical
considerations and image artifacts that might be encountered with
micro-CT (for an overview of these processes see Holdsworth and
Thornton, 2002; Schambach et al., 2010; Wise et al., 2013). Image
acquisition uses a micro-CT scanner, of which a number of different
models and vendors are available. The specimen, which may
consist of one or multiple euthanized fetuses, is scanned with a
predetermined set of X-ray settings that results in a set of two-
dimensional (2-D) images called projection data. The precise X-
ray settings (e.g., the voltage, current, and exposure time) along
with scanning protocol (e.g., total number of projections, and
angular step of rotation) and reconstruction protocol (e.g., range of
CT value, misalignment compensation, ring artifacts and beam-
hardening corrections) are critical for proper image quality and
subsequent image analysis, and thus their determination requiresTable 1
Workshop session and speaker presentations.
Session/Theme Spe
Introduction to imaging technologies and
micro-CT for fetal skeletal evaluations
Ove
H
Intr
An
Mic
H
Deﬁning concordance criteria Pan
Sa
Ju
Xi
Su
Principles of validation Reg
Zh
Reg
Jo
GLP
Le
The future of micro-CT Lon
Lu
Aut
Be
Feta
M
High
Cethe knowledge of an experienced operator. These system parame-
ters may differ across laboratories, and once settings are deter-
mined that result in adequate image quality, then the entire
operation of the micro-CT system needs to be formally speciﬁed in
an SOP.
Image reconstruction involves submitting the radiographic
projection image-set to CT image reconstruction software that
converts the image-set to 2-D tomography images, and lastly for a
3-D CT image. Each micro-CT scanner has a deﬁned ﬁeld of view,
which may accommodate one or many fetuses. The reconstructed
CT image can display 2-D or 3-D images in a similar ﬁeld of view. If
needed, the reconstruction software is able to subsequently “stitch”
together multiple successive scans of a specimen that is larger than
the imaging ﬁeld. If there are multiple fetuses within the recon-
struction, then it will likely be necessary to create a separate image
ﬁle (either manually or by automation) for each fetus. The program
and parameters used for proper reconstruction and fetus identiﬁ-
cation need to be determined by each laboratory, and should be
speciﬁed in a SOP.
The bone mineral density of skeletal elements is not a routine
output from nonclinical micro-CT scanners, but would require
placement of standards of known density (i.e., density phantoms)
into the scan ﬁeld of view, and subsequent calibration of the images
to the phantoms. However, the presenters believe that skeletal
images without absolute bone density calibration can be
adequately evaluated by visual examination. It was emphasized
that communication and collaboration between the imaging group
and the technical staff involved with the evaluation of fetal
morphology is needed to ensure that acceptable images are
generated.
The resolution of images generated by the scanner must be able
to differentiate small skeletal elements, ossiﬁcation status, and
separation of adjacent elements for adequate evaluation. It is up to
each laboratory, especially the individuals who will perform the
evaluation of bone morphology, to assure the quality of generated
images for subsequent evaluation. The conducting laboratory
should determine the spatial resolution of the generated images, as
needed. Although no speciﬁc range was recommended, it wasaker topic & Speaker(s)
rall goals to workshop
oward Solomon (GlaxoSmithKline)
oduction to imaging technology
tong Chen (Merck) presenting for Chris Winkelmann (Pﬁzer)
ro-CT methodology
asan Alsaid (GlaxoSmithKline)
el Presentations
ndra Wood (Merck)
lian French (Morphology Consulting Ltd.)
aoyou Ying (Sanoﬁ)
san Makris [United States (US) Environmental Protection Agency (EPA)]
ulatory perspectives - GLP (21 CFR Part 58)
ou Chen [US Food and Drug Administration (FDA)]
ulatory perspectives - Part 11
nathan Helfgott (Stage 2 Innovations)
validation of technologies, software, and procedures
lia Scott (Charles River Laboratories)
gitudinal study to follow-up a developmental abnormality
c De Schaepdrijver (Janssen Research and Development)
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mately 185 mm was adequate for evaluation of gestation day (GD)
21 rat and GD 28 rabbit fetuses (Winkelmann andWise, 2009;Wise
et al., 2013). There is an inverse relationship between resolution
and scan time as well as ﬁle size (i.e., higher resolution necessitates
longer scan time and larger image ﬁle size). The aforementioned
resolution of 185 mm allowed for scanning of up to approximately
400 rat fetuses per hour, which is adequate to process a typical daily
number of scheduled litters in an EFD study (Winkelmann and
Wise, 2009; Wise et al., 2013). The ﬁle size for one reconstructed
fetal rabbit image (at 185 mm resolution) can be approximately
200 MB and highlights the need for adequate resources for image
archive capacities.
Lastly, the visualization of the fetal skeletal structures may uti-
lize third-party (commercially available or freeware-supplied)
software to analyze the reconstructed 2-D or 3-D image on a
computer monitor. These image processing and viewing worksta-
tions will generally require enhanced graphics capabilities with
high-end graphics processor unit and at least 32-bit high-deﬁnition
resolution. Specimens may be viewed by either surface or volume
rendering of the skeletal elements (Udupa et al., 1991), and each
rendering technique may be adjusted to view different densities by
the selection of speciﬁc threshold values for each voxel (a volume
element, the 3-D version of a pixel). Identiﬁcation and correction of
typical image artifacts were recognized as important aspects of
obtaining high-quality images.
The last presentation in this session addressed the evaluation of
fetal skeletal images from micro-CT as conducted at the laboratory
where the process of scanningmultiple fetuses has been previously
described (see Winkelmann and Wise, 2009). It was pointed out
that this laboratory uses an in-house developed software to sepa-
rate individual fetal images from a single reconstructed image of
multiple fetuses, most often comprised of one litter. That custom
software programwas also required by their institution to undergo
a validation process. A comparison of fetal skeletons evaluated after
alizarin red staining and micro-CT scanning showed a limited
number of subtle differences at speciﬁc regions in both rats and
rabbits. As pointed out by others (Wise andWinkelmann, 2009a, b;
Wise et al., 2010) these differences involve very small and thin
skeletal elements (e.g., short/hypoplastic or supernumerary ribs;
and absent or incompletely ossiﬁed hyoid, sternebral or vertebral
centra, phalanges, metacarpals) that are not easily detected by
micro-CT due to the 185 mm spatial resolution generated by the
scanner. However, it is important to note that in complex structures
comprised of multiple skeletal elements such as the sternum,
vertebral column, digits, and paws, most skeletal elements are
captured usingmicro-CT. The relatively low incidence of these non-
concordant ﬁndings, which were generally not considered by the
laboratory to be malformations but rather variations, are typically
spread across all dose groups, and importantly have not compro-
mised the overall conclusions of those referenced studies. In
addition, these subtle skeletal differences will likely decrease as
newer scanners emerge with higher resolutions and improved
acquisition times. The presentation highlighted the need for
adequate training of evaluators, a peer review process during the
evaluations, and separate historical control data for each type of
evaluation (i.e., alizarin red vs. micro-CT).
2.2. Workshop break-out session e methodology & quality control
Workshop participants divided into ﬁve groups in order to
discuss and collect feedback on issues relating to the previously
described presentations. Speciﬁcally, groups were asked to address
the following four discussion topics: (1) criteria for micro-CT
scanner calibration and performance, (2) the need for inter-laboratory consistency, (3) the criteria for acceptable images, and
(4) the criteria for conﬁrming an observation. The focused breakout
group discussions allowed the organizers to gather perspectives
and feedback from the scientists representing a range of disciplines,
experience, and afﬁliations.
2.2.1. Micro-CT scanner calibration and performance
Given the complexity of micro-CT scanners, the assessment of
proper performance is critical and dictates the need for equipment
and performance checks at routine intervals. Calibration of the
micro-CT scanner is initially conducted on site by an imaging
expert, and thereafter, with conﬁrmation of this calibration, by on-
site users prior to image acquisition. The procedures to assess
performance will vary across laboratories with different scanners,
although there are general calibration principles that can be taken
from the use of CT scanning practice (ACR, 2013). At a minimum,
calibration of the images should be conﬁrmed with phantoms (for
example, density standards and spatial resolution phantoms) based
on the animal species being scanned, speciﬁcally in the range of
densities of the objects of interest, in this instance fetal bone of a
particular species. Other performance criteria (e.g., noise charac-
teristics) can also be assessed, but image scaling calibration and
spatial resolution are paramount. The frequency of assessing per-
formance will be laboratory speciﬁc, but should occur at least
monthly or quarterly, depending on the frequency of use. A
checklist or ﬂow-chart is recommended to determine when a
scanner does not meet performance criteria (i.e., all/most tolerance
limits exceeded), in which case the scanner would be deemed “out
of order” and requiremaintenance or repair.Workshop participants
agreed that the processes to assess performance, as well as routine
maintenance and training of personnel, must be speciﬁed in SOPs.
2.2.2. Need for inter-laboratory consistency
Although inter-laboratory consistency of procedures and results
is always desirable in order to gain reliability of a method, work-
shop participants agreed that it was more important for a given
facility to demonstrate intra-laboratory consistency. Achieving
inter-laboratory consistency is not considered realistic given a
number of issues such as the differences in equipment and settings,
software, facilities, animal models, technical training, and exper-
tise. However, inter-laboratory harmonization can be maximized
with references that describe normal and abnormal skeletal
development (Makris et al., 2009; Strong, 1925; Szabo, 1989; Tyl
and Marr, 2006; Yasuda and Yuki, 1996). There was consensus
among all participants that the procedures to obtain images for
skeletal evaluation within a given laboratory must be consistent,
reproducible, and well understood by laboratory personnel in order
to ensure that reliable data are generated.
2.2.3. Developing criteria for acceptable quality images and for
conﬁrming ﬁndings
Given that alizarin red-stained fetuses have been the “gold
standard” up to now (Dawson, 1926; Peltzer and Schardein, 1966;
Staples and Schnell, 1964), the workshop participants agreed that
the criteria for acceptable micro-CT images must be concordant
with stained fetuses, for both normal and abnormal skeletons from
negative (e.g., vehicle-treated or untreated) or positive controls. In
addition, evaluators must be able to identify common image ﬁnd-
ings/artifacts such as mechanical damage to skeletal specimen (e.g.,
broken rib), beam-hardening, ring artifact, and irregular stitching
(see Barrett and Keat, 2004).
2.2.4. The criteria for conﬁrming an observation
The criteria for conﬁrming a positive ﬁnding should currently
follow the training and processes already in place for a given
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studies necessary to achieve or demonstrate intra-laboratory con-
sistency between individuals and across studies. Since it is neces-
sary to accurately identify both normal and abnormal skeletal
structures (e.g., from a small number of positive control studies),
there was general agreement that conducting a small number of
positive control studies using a minimum number of litters would
be useful. Not all possible skeletal abnormalities will be contained
within this assessment, but a range of common abnormalities is
expected to be included.
3. Concordance criteria and scientiﬁc agreement
It was generally agreed that “concordance” is deﬁned here as the
similarity between traditional alizarin red-stained and micro-CT
scanned fetuses. All levels of personnel from evaluators to man-
agement within each company intending to submit data from
micro-CT images to a regulatory agency must be assured of data
integrity, especially with regard to evaluation of fetal skeletons.
Ultimately the regulatory agencies, who are accustomed to seeing
data sets obtained using the traditional method, must understand
how any new method of fetal evaluation compares. The outcomes
of a panel presentation and the subsequent break-out session that
were organized to address this issue are presented below.
3.1. Background on concordance
A panel of scientists from industry and regulatory agencies
presented their perspectives on concordance between micro-CT
and traditional staining methods. It was pointed out that the
identiﬁcation of abnormalities may vary slightly across labora-
tories. The criteria for identifying skeletal abnormalities, either
stained or scanned, is dependent on recognized standards for
characterizing and classifying fetal abnormalities, and the extent of
training and experience of each evaluator. This training teaches the
technicians the range for skeletal normality. Panelists acknowl-
edged that whereas the training program in each laboratory must
be repeated consistently for all evaluators, some degree of variation
within and between laboratories is acceptable. As such, a peer re-
view process within each laboratory should also be established. The
panelists also noted that there are acceptable variations in the
processing for alizarin red staining across laboratories (e.g., ﬁxative
used, concentrations, temperature, automated, manual, etc.). The
exact procedure of staining and the use (or not) of magniﬁcation for
subsequent evaluation also contribute to acceptable differences in
the criteria for judging normality.
3.2. Workshop break-out session e developing concordance criteria
Workshop participants divided into the same groups, where
they delved into speciﬁc issues related to the concordance between
technologies. The following discussion topics were addressed:
demonstrating adequate concordance, patterns of observation be-
tween micro-CT and stain, the possible inﬂuence of this technology
on the study lowest-observed-adverse-effect level (LOAEL) or no-
observed-adverse-effect level (NOAEL), and performing inter-
laboratory validation.
3.2.1. Demonstrating adequate concordance
This topic generated considerable discussion. It was clear that
there is no single concordance criterion that would fully represent
the similarity/difference between the twomethods. One issue is the
unit for determining concordance of ﬁndings. Concordance could
be based on the ﬁndings of each skeletal component, of each fetus,
or on the group of fetuses within a litter or treatment group. Therewas consensus among workshop participants requiring a very high
level of concordance when it comes to identiﬁcation of skeletal
malformations, both on an individual skeletal element and fetal
level. Furthermore, it was recommended that each laboratory
perform and report the results of concurrent evaluations of stained
and micro-CT scanned fetuses, ideally under blinded conditions,
until an accepted level of conﬁdence is achieved. Such evaluations
may involve using previously stained fetuses (Ying et al., 2011).
Conﬁdence in micro-CT generated data generally, and in the labo-
ratory particularly, would be based upon a consistent incidence of
ﬁndings in negative and/or positive historical control specimens. In
conclusion, deﬁning the acceptable level of concordance for micro-
CT fetal evaluations was deemed to be the responsibility of the
individual laboratories, contingent upon regulatory review. The
benchmark for an acceptable level of conﬁdence must involve
comparison to stained fetuses, but the way to achieve that result
was not deﬁned during the workshop because it will be demon-
strated by each laboratory. Workshop participants agreed that it
was not necessary at this stage to compare staining andmicro-CT in
fetuses collected within a full-GLP study intended for regulatory
submission, but that concordance could be supported from the
results of smaller or previously conducted or historical studies. It
was also highlighted by the regulatory participants that labora-
tories utilizing micro-CT skeletal evaluations should consider sub-
mitting historical control data from both evaluation methods.
Eventually historical control data from stained skeletons will be
unnecessary as micro-CT historical control data becomes more
robust and gains regulatory acceptance. One workshop participant
indicated that their company has provided to regulatory agencies
developmental toxicity reports in which fetal skeletons were
examined solely by micro-CT imaging.
3.2.2. Patterns of observation between micro-CT and stain
The workshop presentations and the experience of micro-CT
users reported that overall, patterns of observation (i.e., malfor-
mations, variations, and incomplete ossiﬁcations in rats and rab-
bits) are similar between the methods. Therefore, the criteria for
determining an abnormal skeletal element are generally similar,
although it was pointed out that speciﬁc criteria may need to be
customized for certain skeletal elements. One such example is the
orientation of sacral vertebral arches in rat fetuses, which may not
be as clearly visible in micro-CT images. Previously published
studies and presentations from this workshop showed that certain
skeletal elements are not resolved by some micro-CT scanning
protocols. Due to the inherent spatial resolution limitations of the
current scanners, very small elements or the separation of
adjoining structures may not be observed. The differences in res-
olution between stained and micro-CT evaluated fetuses are not
considered to be a major concern because they occur infrequently
according to the experiences of some workshop participants. In
addition, alterations in the extent of ossiﬁcation of very small
skeletal elements are commonly encountered with alizarin red
staining due to natural variability of fetal growth and maturation.
The previously discussed publications comparing micro-CT scan-
ned to alizarin red stained fetuses did not ﬁnd this variability in
ossiﬁcation to be a major issue (Winkelmann andWise, 2009;Wise
and Winkelmann, 2009a, b; Wise et al., 2010). Participants recog-
nized that micro-CT would not be able to distinguish alterations of
cartilage. However fetal cartilage examination is not speciﬁcally
required under pharmaceutical guidelines (ICH, 2005) or interna-
tional chemical testing guidelines (OECD, 2001). EPA chemical
testing guidelines indicate that for fetal rodent skeletons, it is
preferable to examine bone and cartilage (EPA, 1998). It is impor-
tant to note that should a situation arisewhere therewere concerns
regarding cartilage development following micro-CT evaluation,
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blue staining and additional examination to resolve any issues. A
ﬁnal point was made that micro-CT has the capability to provide
quantitative measurements that cannot be easily assessed with
alizarin staining technology (e.g., individual bone length, volume,
and density); the usefulness of such data may offset other limita-
tions of micro-CT in the overall evaluation by regulators of the
adequacy of micro-CT to assess risk.3.2.3. Potential effect of micro-CT data on the LOAEL/NOAEL
There was agreement among workshop participants that the
doseeresponse relationship for adverse ﬁndings that are used to
establish the developmental NOAEL/LOAEL should be concordant,
whether using the alizarin red staining method or the micro-CT
imaging method for skeletal evaluation. Intra-laboratory valida-
tion procedures could include studies using positive control sub-
stances in which fetal skeletons are processed by both the alizarin
red staining method and the micro-CT imaging method to deter-
mine if the doseeresponse relationship and NOAEL/LOAEL remain
the same. One workshop participant reported a small number of
studies in which a lower NOAEL/LOAEL was determined for the
incidence of incomplete ossiﬁcation of skull bones (skeletal varia-
tions) in data from stained vs. micro-CT fetuses. This outcome could
suggest the need for a review and modiﬁcation of the settings for
the micro-CT scanner to determine if images might be obtained
that more closely match stain data.
Additionally, as discussed previously, with 185 mm resolution
certain skeletal elements may be difﬁcult to image by micro-CT
based on the normal variability in skeletal ontogeny and extent of
ossiﬁcation (e.g., distal caudal vertebrae, distal phalanges, or small
supernumerary ribs). One participant noted that using 90 mm res-
olution increased the ability to visualize these structures. The
distinction between detecting the ossiﬁcation of a normal skeletal
element (e.g., a caudal vertebra) and detecting the presence of an
abnormal element (e.g., a cervical rib) may be important. However,
each skeletal element represents a metric toward assessing the
skeletal development of the entire fetal skeleton, and their devel-
opmental state may not accurately represent or correlate to that of
the entire fetal skeleton which may otherwise be normal. The
extent of ossiﬁcation of these elements should be considered
together. When interpreting the results of validation studies that
use both skeletal evaluation techniques, consideration should be
given to the overall extent of skeletal development, patterns of
developmental variation, and what is known about the severity or
persistence of ﬁndings. Taking these considerations into account
might result in greater concordance of NOAELs and LOAELs.3.2.4. Performing inter-laboratory validation
Although an inter-laboratory collaborative study was consid-
ered to be potentially useful, there was a consensus that this was
not a high priority at this time. At this stage of development, the
priority is on the achievement of intra-laboratory cross-study
consistency facilitated by training and experience in micro-CT.
Some of the complexities of an inter-laboratory study were
nevertheless discussed, and two methods for assessing similarities
in scanning and assessment procedures and outcomes were pro-
posed. A set of preserved fetuses could be distributed among a
number of laboratories to determine if each could generate similar
scans that are similarly interpretable. Alternately, a set of images
generated at one laboratory could be distributed to other labs to
assess the ability of participants to detect similar ﬁndings. Speciﬁc
goals and methods of an inter-laboratory study would require
further discussion.4. General principles of validation
This session of the workshop was intended to provide partici-
pants with the regulatory expectations involved in implementing a
new technology such as micro-CT into the GLP environment. The
presentations in this session primarily referenced the US FDA reg-
ulations applicable to nonclinical studies (21 CFR Part 58 [GLP
principles] and Part 11 [electronic records & signatures]), but the
same principles will apply toward studies intended to comply with
US EPA and OECD guidelines. Based upon the workshop pre-
sentations, it was clear that all micro-CT systems are computer
based, consisting of hardware and software components. When the
generation, measurement, or assessment of data is intended for
regulatory submission, such systems are required to be developed,
validated, operated, and maintained in compliance with GLP prin-
ciples. With the intention of utilizing micro-CT for fetal skeletal
evaluations as part of standard EFD studies, users must apply such
principles to both the in-life portion as well as post-mortem
components, including the overall micro-CT system and
procedures.
4.1. Background on principles of validation
The ﬁrst presentation provided an overview of GLP consider-
ations when imaging technologies are used in regulatory EFD
studies. Many of the same criteria mentioned previously regarding
technical considerations (e.g., consistent results comparable to
traditional evaluation, documented evidence) were emphasized as
being necessary for proper validation. Documentation already
produced for all in-life aspects of study conduct [e.g., facility
management, Study Director duties, laboratory personnel, quality
assurance unit (QAU), etc.] may be applicable to the micro-CT
component of the study. Additional SOPs of sufﬁcient detail will
be required for the operation and maintenance of the micro-CT
system, including the identiﬁcation of responsible personnel. The
entire conduct of a given study would follow the prescribed pro-
tocol and SOPs. As with the in-life portion of a study, the genera-
tion, security, storage, and ﬁnal disposition of data will need to be
documented.
The second speaker presented a clinical perspective to focus on
issues related to computer components. The FDA assesses a mini-
mum threshold for compliance through regulatory requirements in
21 CFR Parts 11, 50, 56, 58, 312, and 812; not all of which are
applicable to nonclinical studies. These regulations are intended to
ensure conﬁdence in the reliability, quality, and integrity of elec-
tronic source data, source documentation, and the computerized
systems used to collect and store the data. Documentation should
cover the categories of personnel training, internal/external secu-
rity safeguards (including backup and recovery procedures), source
documentation and retention, audit trails, speciﬁc system features,
and SOPs. It is important to identify and document the speciﬁed
requirements for the system, and ensure that the computerized
system is capable of consistently meeting all of these speciﬁed re-
quirements. All micro-CT systems are speciﬁed by the vendor, so
documentation addressing validation or user acceptance testing
will be necessary in the future.
The ﬁnal presentation discussed the validation challenges for
imaging technology in a regulated environment. These challenges
are not unique to micro-CT systems but also apply to other systems
that produce digital images (e.g., histopathology, computer-
assisted sperm analysis). Challenges include controls to prevent
image modiﬁcation, audit trails, and the general complexity of
image analysis validation. The challenges must be weighed against
the many potential beneﬁts, such as lack of specimen degradation
and enhanced ease of sharing and peer-reviewing, organizing, and
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is that it can be designed to be objective and reproducible. An
example of a list of validation documentation and SOPs that would
be applicable to a micro-CT system used in regulatory nonclinical
study is shown in Table 2.
The recommended validation deliverables are expected stan-
dard documents and may include more detailed documents. For
example, the installation qualiﬁcation (IQ) may also include an IQ
plan, test scripts, and a separate summary report. The inclusion and
details of these documents are dependent on the process estab-
lished at each laboratory/company. The SOPs listed in Table 2 are
generally those that would be needed to support each regulated
computer system. Depending on company policies, the topics may
already have been incorporated into other existing procedures
applicable to many computer systems. For instance, several of the
indicated topics may be combined into a single procedure. Com-
panies typically would assign a Validation Project Manager who
would be responsible for verifying that all required areas described
in Table 2 are addressed or deemed not applicable. Approval of the
validation summary report is contingent upon completion and
veriﬁcation of all required SOPs. The validation SOP would provide
the scope and expectation for validation of computer systems,
deﬁne the deliverables listed above, and specify the responsibilities
of the validation project team, including the QAU, information
technology, users and management.4.2. Workshop break-out session e considerations for GLP and
electronic data acceptance criteria
Participants divided into the same ﬁve groups to discuss issues
relating to the regulatory compliance, including the following: (1)
complying with 21 CFR Part 11 (electronic) and Part 58 (laboratory
practice), (2) deﬁnition of raw data, and (3) ensuring data integrity.4.2.1. Complying with 21 CFR Part 11 (electronic) and 21 CFR Part
58 (laboratory practice)
A suggestion was made that the validation process for micro-CT
hardware and software components would be similar to any other
piece of technical equipment needed to conduct GLP-compliant
studies. All laboratories conducting GLP-compliant nonclinical
studies would likely have validated vendor-supplied systems.
However, many of the vendor-supplied systems for micro-CT
scanning are not Part 11 compliant. For example, in the absence
of a fully compliant audit trail, controls can be put into place to
ensure the image could not be modiﬁed (e.g., read-only ﬁle). Par-
ticipants recognized that SOPs should be available for all aspects of
the process and each piece of equipment, but the group agreed that
there will be no need to harmonize SOPs among laboratories.Table 2
Recommended procedures for computer system validatio
environment.
Validation process SOPs
Validation Plan (VP)
System Conﬁguration Speciﬁcations (SCS)
System Requirement Speciﬁcations (SRS)
Installation Qualiﬁcation (IQ)
Operational Qualiﬁcation (OQ)
Performance Qualiﬁcation (PQ)
User Acceptance Testing (UAT)
Validation Summary Report (VSR)
Traceability Matrix (TM)
System Commissioning Memo (SCM)4.2.2. Deﬁning raw data
The participants also discussed what constitutes the raw data in
terms of image collection and evaluation. They were reminded that
each scan from a micro-CT system generates a ﬁle of projection
data, reconstructed CT images (2-D or 3-D images), possibly indi-
vidual fetal images, and associated electronic or hard copy records
documenting the skeletal evaluation. The initial projection data ﬁle
can be large in terms of memory storage and cannot be displayed
directly for morphological evaluations. After reconstruction of the
projections, the ﬁles or more likely the individual fetal images
would be used for the skeletal evaluation. The software used to
view such ﬁles may change over time. New software may be unable
to manipulate and view legacy ﬁles. Some participants considered
the reconstructed images, and the recorded evaluation and inter-
pretation of fetal skeletal ﬁndings as the raw data, but not the
stained fetus or micro-CT image. This is presented as conceptually
similar to recording physical/clinical signs of a live animal. Another
point of view expressed was that all iterations of the image,
including the original projection data ﬁle, should be considered as
raw data. Each image actually used by laboratory personnel to
make the evaluations of skeletal morphology should be kept as raw
data. Additionally, participants agreed that the raw data archived
must allow for the necessary reconstruction of the study per GLP
regulations. Workshop participants were not aware of relevant
regulatory guidance. Each laboratory is encouraged to work with
their internal QAU on this matter to meet regulatory and customer
expectations. It should be noted that recent regulatory guidance
indicates that the original data ﬁle and any modiﬁcation, process-
ing, etc. done to that ﬁle need to be retained to reproduce the study
(FDA, 2010).
4.2.3. Ensuring data integrity
Workshop participants agreed that by its nature, electronic 2-D
or 3-D image data would be maintained on some form of memory
storage, such as hard disks or servers as in a picture archiving and
communication system. Furthermore, all ﬁles should be in a “read-
only” format in order to prevent editing of an image. Laboratories
will need to consider the amount of storage needed and whether
long-term storage will be on- or off-site (i.e., provided by an in-
dependent vendor). Issues of security, access, audit trails, and
annotation (e.g., meta-data identifying such attributes as date,
location, scanner, study, group, animal number, etc.) will also need
to be addressed. The participants agreed that all of these issues are
not unique to micro-CT systems and will likely have already been
addressed for other systems.
5. Future research and paths forward
The ﬁnal session of the workshop consisted of four pre-
sentations that highlighted alternative applications of micro-CTn, use, maintenance, and operation in a regulated
Use, maintenance, and operation SOPs
Computer System Operation
Computer System Administration
Preventative/Routine Maintenance
Change Control
User/Administrator Training
Security
System Back-up and Disaster Recovery
Virus Protection (System Protection)
Archival or Regulated Electronic Records
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studies.
5.1. Imaging for visceral evaluation
The potential for using imaging modalities to phenotype mouse
fetuses were discussed. Experiences using MRI and optical projec-
tion tomography to examinemouse embryos with the use of micro-
CT conducted in collaboration with the International Knockout
Mouse Consortium to phenotype mouse fetuses (Wong et al., 2012)
were described. To assess new gene knockout fetuses, a 3-D atlas of
48 normal structures was developed that is able to align and
analyze micro-CT scans of test fetuses to reveal alterations of
visceral structures by volume analysis, which is aided by staining
the viscera with a contrast agent; this work is continuing by
building a continuous 3-D spatial atlas of the mouse fetal devel-
opment (i.e., GD 11.5 to 14).
The use of high-throughput imaging modalities to phenotype
structural birth defects in mice when exposed via maternal treat-
ment with N-ethyl-N-nitroso-urea (Kim et al., 2013; Liu et al., 2014)
was described. The use of non-invasive in-life fetal echocardiog-
raphy (i.e., ultrasound) for cardiovascular phenotyping, with
follow-up virtual necropsies using micro-CT, MRI, and episcopic
confocal histopathology was also described. Examples demon-
strated the capabilities of their methods to reveal abnormalities of
the heart as well as other visceral structures.
As noted in the presentations, micro-CT imaging visualization
may currently require the use of a contrast agent for the staining of
soft tissue evaluations whereas other imaging modalities do not
(e.g., MRI). Fetal visceral imaging and evaluation in EFD studies is
not time- or cost-effective for any imaging modality at the present
time.
5.2. Longitudinal studies
One advantage of micro-CT evaluation of the developing skel-
eton is that sacriﬁce of the animal is not required, allowing for
longitudinal analysis. Presentations on the use of micro-CT to
analyze bone morphology in postnatal and full term rat fetuses in
order to examine the postnatal fate of skeletal abnormalities that
were originally detected in uterowere summarized. The goal was to
provide information for correct classiﬁcation of the abnormalities
(i.e., malformation or variation) as it relates to their reversibility
and effects on survival and health of the treated animal (De
Schaepdrijver et al., 2014). Control and treated dams were
allowed to deliver naturally at term and their anaesthetized
offspring were examined by micro-CT scans on postnatal days 0, 7,
21, and 80. To obtain bone length, width, volume, and bending
parameters, a customized semi-automated process was developed
by Deﬁniens AG (Germany) to detect fore- and hind-limb skeletal
elements, followed by an analysis (including statistics) of bone at-
tributes. The results presented showed that treatment-related bent
long bones in the fetuses were transient, showing complete re-
covery within 3 weeks after birth, and therefore this abnormality
could be classiﬁed as a variation instead of a malformation. Thus,
postnatal longitudinal studies using micro-CT have the potential to
reduce uncertainties regarding classiﬁcation of abnormalities and
add valuable information for use in risk assessment decisions
regarding drug safety.
5.3. Automated skeletal analysis
Application of image analysis techniques for automated,
repeatable, quantitative, and objective analysis of skeletal bones to
high throughput micro-CT images of rabbit fetuses (Chen et al.,2014; Dogdas et al., 2015) was presented. In object-oriented im-
age analysis, the image is segmented into smaller elements for
further classiﬁcation based on color, shape, size, texture, pattern,
and context information. Automated identiﬁcation of abnormal
skull and torso skeletal bones are performed through the use of
image registration, segmentation, and mining techniques. Regis-
tration is a mathematical mapping technique performed as an
initial step to align the images onto a common coordinate frame by
transforming an image relative to another so that corresponding
features in the two images have the same coordinates to accom-
modate more consistent segmentation process (Brown, 1992;
Maintz and Viergever, 1998; Zitova and Flusser, 2003). In theory,
this type of analysis could be used across laboratories resulting in
more uniform assessments of skeletal morphology in GLP-
compliant EFD studies.
6. Conclusions
This workshop provided a forum for key stakeholders from
government, industry, and academia to discuss the current state of
the science as it relates to fetal imaging with micro-CT. The work-
shop discussed the utility of the technology for developmental
toxicity testing and ways to facilitate the acceptance of alternative
imaging methods for evaluating structural anomalies in animal
models. Participants were able to come to consensus on two main
issues. First, there was agreement among participants that micro-
CT systems, although complex, have an immediate usefulness in
regulated EFD studies. Secondly, that intra-laboratory consistency
of scanner operation and maintenance, evaluation criteria, and
SOPs are a higher priority than inter-laboratory concordance in
order to move the ﬁeld toward greater acceptance of the methods.
The workshop participants formulated the following minimal
criteria for the proper company- or laboratory-speciﬁc imple-
mentation of the micro-CT technology, which would be necessary
for scientiﬁc acceptance by a regulatory agency:
1) Establishing and documenting scanning operation, calibration,
and maintenance; and identiﬁcation and training of appropriate
personnel.
2) Determining and documenting an acceptable level of concor-
dance between alizarin red-stained and micro-CT imaged
fetuses.
3) Creating and completing a set of validation deliverables, which
depend on company policies and are based on regulatory
guidelines.
4) Writing a complete set of SOPs covering all aspects of hardware
and software for the use of micro-CT.
Establishing these scientiﬁc acceptance requirements for micro-
CT examination among a group of experts frommultiple sectors is a
successful ﬁrst step towards acceptance of these data by regulatory
agencies, a goal that has not yet been achieved. In addition to the
success of developing acceptance criteria for micro-CT in a labo-
ratory, this workshop represented a fruitful, positive educational
collaboration that initiated positive communication among in-
dustry, regulatory, and academic scientists. As this communication
continues, and as additional laboratories incorporate imaging
technologies and technology advances in speed and capabilities,
the future goal of regulatory acceptance could be achieved, allow-
ing replacement of older methodologies.
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